Back to News
Market Impact: 0.4
Vaxcyte's VAX-31 Meets Key Phase 3 Goals Against Prevnar 20 And Capvaxive; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Vacyte (PCVX) reported positive topline results from its pivotal Phase 3 OPUS-1 trial, with VAX-31 meeting all prespecified primary endpoints in adults. The brief report provides no endpoint measurements or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
PCVX0.85
More News
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Vaxcyte shares surge on late-stage vaccine trial success
- Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more
- Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
- Stock Movers: Vaxcyte, Harley Davidson, CH Robinson (Podcast)
- Dow Gains 100 Points; ISM Services PMI Falls In September